Objective: to evaluate the dynamics of the markers of oxidative stress in patients with chronic obstructive pulmonary disease (COPD) during the application of atorvastatin. Material and methods. The study included 52 COPD patients with concomitant hyperlipidemia. The main group (n = 30) were given atorvastatin at a dosage of 20 mg per day in addition to the standard COPD treatment. The comparison group (n = 22) only underwent the standard COPD treatment. The patients were monitored for 24 weeks. The levels of superoxide dismutase, catalase and malondialdehyde were evaluated for the assessment of oxidative stress. Results. In the group of the patients taking atorvastatin, the level of superoxide dismutase decreased from 949 [608; 1042] units/ml initially to 406 [319; 478] u/ml after 24 weeks (p = 0.035). The levels of catalase and malondialdehyde did not change significantly both in the experimental and comparison groups. Conclusion. The intake of atorvastatin decreases the level of superoxide dismutase, which may indicate a decrease in the level of oxidative stress in COPD patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.